Introduction
The skin, the largest and most accessible organ in the body, is an attractive target for somatic gene therapy. It is readily available for topical application and intradermal injection of genetic materials is a simple procedure. [1] [2] [3] [4] [5] In general, genetic modification of the skin can be performed ex vivo or in vivo. For ex vivo gene transfer, cells are grown from skin biopsies and genetically engineered in vitro before grafting, whereas for in vivo transduction, the genetic material is administered directly into intact skin. Gene transfer technology for intact skin or cells is an important approach that can be applied to several fields ranging from basic research to innovation in the development of novel clinical modalities.
The use of viral vectors in meditating gene transfer has been examined intensively for therapeutical usage of inherited skin diseases such as Dystrophic Epidermolysis Bullosa, [6] [7] [8] [9] Junctional Epidermolysis Bullosa (JED), [10] [11] [12] Lamellar ichthyosis, 13 and X-linked ichthyosis. 14, 15 Several types of viral vectors such as retrovirus, adenovirus, adeno-associated virus (AAV) and lentivirus have been evaluated for epidermal gene transfer in vivo. [16] [17] [18] [19] [20] [21] Adenovirus vector can efficiently transduce keratinocytes, however, transgene expression is transient owing to the loss of unintegrated vector during epithelium differentiation as well as immunodestruction of target cells. 22 Retroviral vectors based on murine leukemia virus (MuLV) can lead to long-term expression of the transgene in keratinocytes both in in vitro 23 and in vivo, 24 probably owing to integration of the genetic material into the host genome. However, transduction is limited to proliferating cells which required intense tissue manipulation such as dermabrasion to create an adequate population of dividing cells. 18, 25 Lentivirus vectors such as HIV-based vector can integrate into the genome of quiescent as well as proliferating cells resulting in stable and long-term expression of the transgene. 26 To optimize transduction of target tissue, the incorporation of the various viral envelope proteins onto the viral membrane of lentiviral vector (i.e. pseudotyping) has been developed. Early pseudotyping mainly involved the use of the vesicular stomatitis virus envelope glycoprotein (VSV-G), which conferred both broadened tropism and increased stability facilitating concentration and storage. [26] [27] [28] It has been reported that a single intradermal injection of VSV-G-pseudotyped HIV-1-based lentivirus into human skin grafted on immunodeficient mice could efficiently transduce most major skin cell types including keratinocytes, fibroblasts, endothelial cells and macrophages within 1 month and persisted for at least 6 months. 20 Pseudotyping lentiviral vector with different envelope proteins has been shown a valuable strategy for optimizing vector tropism to a specific tissue of interest. Up to date, several pseudotyped lentiviral vectors using surface glycoproteins from various viruses were re-targeted or targeted with improved efficiency to different organs or tissues such as liver, lung, muscle and islets. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] In the present study, HIV-based vector was pseudotyped with the envelope glycoprotein of VSV, Zaire Ebola virus (EboZ), MuLV, lymphocytic choriomeningitis virus (LCMV), Rabies virus or the rabies-related Mokola virus and evaluated for efficacy and cell type specificity following transduction of human skin grafted onto severe combined immunodeficient (SCID) mice. Transduction efficiency was evaluated qualitatively and quantitatively within the time frame of epidermal renewal (4 weeks), where the replication of stem cells and transit amplifying cells undergo differentiation and desquamation. EboZ-, MuLV-and VSV-G-pseudotyped lentiviral vectors effectively targeted quiescent epidermal stem cells as well as the proliferating daughter cells. The quantitative analyses of b-galactosidase expression and numbers of integrated transgene in genomic DNA indicate that VSV-G-pseudotyped lentiviral vector is more suitable for cutaneous transduction of human skin in the xenograft model.
Results

Production of adenovirus and pseudotyped HIV-based vectors
The following viral envelope glycoproteins were used for pseudotyping HIV-1-based vector: envelope glycoprotein of VSV-G, EboZ, MuLV, LCMV, Rabies or Mokola virus. All pseudotyped viruses were produced in parallel under the same conditions for every experiment. 
Localization of transgene expression during epidermal turnover
The cutaneous transduction patterns of lentiviral vector pseudotyped with VSV-G, EboZ, MuLV, LCMV, Rabies or Mokola glycoproteins were qualitatively evaluated by immunocytochemistry with specific antibodies against b-galactosidase, integrin b1 (marker for stem cell and basal cell), involucrin (differentiation marker of keratinocyte) or fibroblast. Human skin xenograft transplants were injected twice with 25 ml (10 mg of p24) at 1 week of interval and excised tissues were analyzed 1 week after the second injection. Results show that b-galactosidase expression was detected at variable levels in the stratum corneum, epidermal keratinocytes and dermal fibroblasts in the skin treated with each pseudotyped HIV vector evaluated (Figure 1) . Notably, VSV-G, EboZ or MuLVpseudotyped vector consistently showed b-galactosidase expression comparable to that of adenoviral vector in human skin epidermis and dermis (Figure 1 and 2) . HIVbased vector-transduced skin showed normal keratinocyte differentiation patterns similar to that of phosphatebuffered saline (PBS) injected control (data not shown), whereas adenoviral vector-induced evident epidermal hyperplasia (Figure 1m 
Transduction of human skin after a single injection
En face visualization of the human skin xenograft transplant after a single injection of VSV-G-, EboZ-or MuLV-pseudotyped vector demonstrated comparable levels of positive staining for b-galactosidase ( Figure 5c , e and g). Interestingly, intense staining was observed in the underlying dermal region when VSV-G-pseudotyped vector was administered (Figure 5d ). To rule out pseudotransduction of b-galactosidase protein generated during vector production, VSV-G-or MuLV-pseudotyped vector was injected in the presence of 100 mM of AZT (zidovudine), which inhibits reverse transcription and thus de novo synthesis of the transgene product. Transduction of human skin with either VSV-G-or MuLV-pseudotyped vector in the presence of AZT resulted in b-galactosidase staining comparable to the untreated negative control xenograft, indicating that pseudotransduction was not responsible for b-galactosidase activity in transduced human skin (data not shown).
Quantitative evaluation of transduction efficiencies by pseudotyped HIV-based vectors in human skin xenografts
Gene transfer efficiency of VSV-G-, EboZ-or MuLVpseudotyped vector was further analyzed by TaqMan PCR to identify the most efficient vector in human skin xenografts. To determine the copy numbers of reversetranscribed vector transgene, TaqMan PCR was performed with primers specific to two regions inside the 
Discussion
Retargeting or expanding tropisms by changing the coat protein responsible for attachment and entry of viral Immunocytochemistry staining of the grafted human skin was performed with a rabbit polyclonal antibody recognizing the E. coli b-galactosidase (red) (a, c, e, g, i, k and m) and merged with a monoclonal antibody specific for human involucrin (green) (b, d, f, h, j, l and n) as detailed in 'Materials and methods'. Bar ¼ 50 mm.
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A Hachiya et al vectors into target cells has been successfully applied to several gene transfer vector systems such as lentiviral and AAV vectors. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] The present study evaluated tropism of HIV-based vector pseudotyped with envelope glycoproteins from VSV, EboZ, MuLV, LCMV, Rabies or Mokola virus for different cell types present in differentiated human skin. Sections (2-4 cm 2 ) of human skin were transplanted onto the back of SCID mice and injected intradermally with each pseudotyped vector preparation. This study shows that among all the pseudotyped HIV vectors evaluated, VSV-G, EboZ-and MuLV vectors consistently transduced fibroblasts in human skin xenografts, at levels comparable to that obtained with adenovirus. In addition, VSV-G, EboZand MuLV-pseudotyped HIV vectors efficiently transduced epidermal progenitor cells with subsequent expression in the epidermis following normal terminal differentiation. This finding is consistent with a recent report, indicating that transgene expression from a VSV-G-pseudotyped HIV vector can be detected along the basal layer and in columns of differentiated epidermal cells in human foreskin xenografts. 39 Long-term expression of a transgene of interest in several cell types of the skin, especially in epidermal stem cells, would be of therapeutic value for inherited skin diseases such as JED, which manifest by a separation of the epidermis from the 
basal lamina forming a blister cavity in the plane of the lamina lucida. [10] [11] [12] In this study, adenoviral vector induced epidermal hyperplasia possibly by inducing secretion of cytokines that regulate epidermal differentiation and proliferation such as IL-1. 40 Expression of b-galactosidase persisted for 28 days in keratinocytes and skin fibroblasts following transduction with VSV-G, EboZ-or MuLV pseudotyped HIV vector. However, anomalies reminiscent of tissue degeneration were observed in the dermis treated with EboZ-pseudotyped HIV vector. Interestingly, skin transduced with LCMV-pseudotyped HIV vector also showed similar tissue degeneration despite low levels of b-galactosidase expression. Toxicity associated with intracellular expression of the Ebola glycoprotein has been reported for different cell type in vitro. 41, 42 However, our observation is the first report indicating that incoming envelope glycoproteins in the context of a HIV vector preparation can be toxic to a human tissue. The mechanism has yet to be elucidated and experiments are currently evaluating the development of human skin xenograft after treatment with a HIV vector pseudotyped with the envelope NTD4L, a deletion mutant of the Ebola glycoprotein, which has demonstrated undetectable toxicity in vitro. 42 In the study outlined here, we demonstrated how pseudotyping lentiviral vector could influence the transduction efficacies of epidermal and dermal skin cells as well as the ability to target the quiescent stem cells. Among the six viral envelopes investigated, VSV-G mediated the most efficient cutaneous gene transfer of HIV-based vector into keratinocyte stem cells and fibroblasts. In addition, no signs of toxicity were detected following transduction with VSV-G-pseudotyped-HIV vector. These findings provide new insights for the development of an efficient gene transfer strategy for cutaneous gene therapy.
Materials and methods
Grafting human skin onto SCID mice and injection of pseudotyped-lentiviral vectors
Animals were handled according to the guidelines of the Institutional Animal Care and Use Committee and Cincinnati Children's Hospital Research Foundationapproved protocol (Cincinnati, OH, USA). ICR-SCID mice 4-6 weeks old (Taconic, NY, USA) were kept under pathogen-free condition (Children's Hospital Research Foundation, Cincinnati, OH, USA) throughout the experiments. After 1 week of acclimation, they were shaved with an electric clipper to remove the dorsal hair. Before the surgery, mice were anesthetized with isofluorane/oxygen (3%/0.8 l) and were maintained using isofluorane/oxygen (2%/0.7 l) throughout the surgery. The shaved dorsal skin was treated with a non-staining surgical scrub upon confirmation of anesthesia. The dorsal site was cut to produce a wound bed of approximately 2.0-3.0 cm in diameter. Cadaveric skin (US tissue and cells, Cincinnati, OH, USA), which were obtained 1 day before the surgery and maintained in Dulbecco's modified Eagle's medium with L-glutamine and antibiotic/antimycotic (Invitrogen, Carlsbad, CA, USA) at 2-41C was sutured in place with a reverse cutting precision monofilament PS-3, 6-0 (Ethicon Endosurgery, Cincinnati, OH, USA). The edges of the graft bed were treated with sensorcaine to provide analgesia. Following the surgery, the mice were kept in an incubator at 371C either for an hour or until recovered from anesthesia.
The viral stocks of pseudotyped-lentiviral vectors with different type of glycoprotein envelopes were RCL-free certified by a vector core at Indiana University. After The integrated E. coli b-galactosidase copy number and b-galactosidase activity is the highest in the skin treated with VSV-G-pseudotyped lentiviral vector compared to the rest of viral vectors. (a) The integrated E. coli b-galactosidase copy number was analyzed after genomic DNA was extracted from each tissue using a DNeasy kit as detailed in 'Materials and methods'. The values represent mean7s.d. of integrated copy number per 100 ng of total DNA from three to four individual grafted skins. (b) b-galactosidase activity was evaluated after pulverized biopsies were lysed in buffer for b-galactosidase assay as detailed in 'Materials and methods'. The values represent the mean7s.d. from three to four individual grafted skins. The activity in the skin treated with VSV-Gpseudotyped lentiviral vector was significantly (Po0.05) higher than those of the rest of viral vectors and the activities in the skin treated with EboZ-and MuLV-pseudotyped lentiviral vector were also significantly (Po0.05 and Po0.01, respectively) higher than the PBS control.
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DNA construction and vector production
The helper packaging construct pCMVR8.2 encoding the HIV helper function, the transfer vector pHxLacZWP encoding Eschericia coli b-galactosidase gene, and plasmids encoding for envelope proteins were used for triple transfection as described elsewhere. 43 Titers of pseudotyped lentiviruses were examined by serial dilution on 293T cells seeded as described elsewhere. 44 Adenovirus vector was prepared using Adeno-X Adenoviral Expression Systems (BD Clontech, Mountain View, CA, USA), according to the manufacture's instructions. The titer of adenoviral stock was determined using Adeno-X Rapid Titer Kit (BD Clontech). In brief, HEK 293 cells were transfected with several dilutions of adenoviral stocks. After 48 h in culture, cells were fixed in methanol and infected cells were detected using an antibody against adenoviral hexon protein.
All experiments involving the production and functional analysis of replication-incompetent HIV-based pseudotyped vectors were performed under biosafety level 2+ containment as approved by the Institutional Biosafety Commitees of both the Wistar Institute and the Cincinnati Children's Hospital.
X-gal staining, immunohistochemistry and confocal microscopy
One and four weeks after the second injection, harvested biopsy specimen was immediately fixed in 0.2% glutaraldehyde for 10 min, followed by the incubation in 1 mg/ml X-gal diluted in 0.1 M sodium phosphate buffer (pH 7.4) with 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 1 mM MgCl 2 , 0.02% NP-40 and 0.01% deoxycholate at 371C overnight. Tissue was trimmed around the blue green staining of X-gal hydrolyses, postfixed in 2% p-formaldehyde and embedded in paraffin and either counterstained with hematoxylin and eosin or proceeded with immunofluorescence. In another set of experiment, the expression level of reporter gene post-transduction was visualized by X-gal staining following 24 h after a single injection.
To examine the transfection efficacy of each vectors in targeting skin cells, the immunoreactivities of E. coli b-galactosidase and several skin markers were investigated using rabbit polyclonal antibody against E. coli b-galactosidase (Abcam; Ab4761, Cambridge, MA, USA), mouse monoclonal antibodies against human CD29 (integrin b1; clone MAR4, BD Pharmingen, San Diego, CA, USA), involucrin (Clone SY5, Labvision, Fremont, CA, USA), and CD90/Thy1 (BD Pharmingen, San Jose, CA, USA). To avoid skin autofluorescence, paraffin sections were deparaffinized and free aldehyde groups from glutaraldehyde/formaldehyde fixation were saturated with 0.25% ammonia in 70% ethanol for 30 minutes, and detected with Quantum Dot nanocrystal (QDot 605 goat anti mouse, biotinylated rabbit antibody and QDot 655 streptavidin conjugated, Hayward, CA, USA), which emits fluorescence in the near-infared region. Normal mouse IgG, and rabbit IgG (Vector Laboratories, Burlingame, CA, USA) were used as negative controls. Double labeling were analyzed using Zeiss LSM confocal laser scanning microscope (Zeiss, Germany) with an excitation wavelength of 488 nm, and emission filter BP 585-615 nm and LP 650 nm for QDot 605 and QDot 655, respectively.
Genomic DNA PCR
Half of a 6 mm punch biopsy collected at the injection site 4 weeks after the second injection was minced and used for genomic DNA extraction using a DNeasy tissue kit (Qiagen) according to the manufacture's instructions.
Viral cDNA integrated host genome was quantified using ABI PRISM 7300 sequence detection system (Applied Biosystems) as described elsewhere. 44 Briefly, each 50-ml of the reaction mixture contained 22.5 ml of gDNA, 0.9 mM each primer, 0.2 mM labeled probe, and 25 ml of TaqMan Universal PCR Master Mix (Applied Biosystems). The TaqMan probe for detection of the integrated pHxLacZWP was labeled with the fluorescent reporter dye 6FAM at the 5 0 end and the quencher dye TAMRA at the 3 0 end (6FAM-AGCTCTCTCGACGCAG GACTCGGC-TAMRA). The following TaqMan primer sets for amplification of the region encompassing the packaging signal of pHxLacZWP were used in this study: sense, 5
0 -TGA-AAG-CGA-AAG-GGA-ACC-A-3 0 , and antisense, 5 0 -CCG-TGC-GCG-CTT-CAG-3 0 . All reactions were set up in MicroAmp Optical 96-well reaction plates (Applied Biosystems). Amplification conditions in the ABI PRISM 7300 sequence detection system were 551C for 2 min and 951C for 10 min, followed by 951C for 15 s and 601C for 1 min and repeated for 50 cycles. Data were collected from the ABI PRISM 7300 sequence detection system and transferred directly to a computer and analyzed using Sequence Detection Software (Applied Biosystems). Unknown samples, standards, and template negative controls were run in duplicate. The frequencies of unknown samples were interpolated from a standard curve derived from the simultaneous amplification of linearized pHxLacZWP plasmid DNA standards. The quantity of vector transgene copies was calculated per 100 ng of genomic DNA.
b-Galactosidase assay
Another half of a 6 mm punch biopsy specimen that was collected at the injection site of each animal 4 weeks after the second injection was pulverized in liquid nitrogen, and transferred to a glass vial. Lysis buffer was added in each vial after liquid nitrogen was completely evaporated. A quick freeze and thaw was done to break up cells. The supernatant was collected after centrifugation at 41C for 5 min. Relative b-galactosidase expression in the supernatant was determined using enhanced b-galactosidase assay kit with chlorophenol red-b-Dgalactopyranoside; CPRG (Gene Therapy Inc., San Diego, CA, USA) and bicinchoninic acid protein assay (Pierce, Rockford, IL, USA) according to the manufacture's instructions.
Statistics
The level of significance of the difference was calculated by the Student's t-test. The differences in the mean or raw values among treatment groups were considered significant when Po0.05.
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